Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: Results of a West Japan Oncology Group study

Oncotarget

Volumn 5, Issue 8, 2014, Pages 2293-2304

  Okamoto, Isamu ^a   Sakai, Kazuko ^b   Morita, Satoshi ^c   Yoshioka, Hiroshige ^d   Kaneda, Hiroyasu ^b   Takeda, Koji ^e   Hirashima, Tomonori ^f   Kogure, Yoshihito ^g   Kimura, Tatsuo ^h   Takahashi, Toshiaki ⁱ   Atagi, Shinji ^j   Seto, Takashi ^k   Sawa, Toshiyuki ^l   Yamamoto, Masashi ^m   Satouchi, Miyako ⁿ   Okuno, Motoyasu ^o   Nagase, Seisuke ^p   Takayama, Koichi ^q   Tomii, Keisuke ^r   Maeda, Tadashi ^s   Oizumi, Satoshi ^t   Fujii, Shinji ^u   Akashi, Yusaku ^v   Nishino, Kazumi ^w   Ebi, Noriyuki ^x   Nakagawa, Kazuhiko ^b   Nakanishi, Yoichi ^a,q   Nishio, Kazuto ^b   more..

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KURASHIKI CENTRAL HOSPITAL   (Japan)

^e OSAKA CITY GENERAL HOSPITAL   (Japan)

^f OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^h OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ SHIZUOKA CANCER CENTER   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^k NATIONAL KYUSHU CANCER CENTER   (Japan)

^l Gifu Municipal Hospital   (Japan)

^m NAGOYA EKISAIKAI HOSPITAL   (Japan)

ⁿ HYOGO CANCER CENTER   (Japan)

^o AICHI CANCER CENTER HOSPITAL   (Japan)

^p TOKYO MEDICAL UNIVERSITY   (Japan)

^q KYUSHU UNIVERSITY   (Japan)

^r KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^s NATIONAL SANYO HOSPITAL   (Japan)

^t HOKKAIDO UNIVERSITY   (Japan)

^u National Hospital Organization   (Japan)

^v KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^w OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^x ASO IIZUKA HOSPITAL   (Japan)

more..

Author keywords

Fusion gene; Genotyping; MET amplification; Non small cell lung cancer; Phase III trial

Indexed keywords

CARBOPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL; ANTINEOPLASTIC AGENT; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ALK GENE; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE REARRANGEMENT; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; JAPAN; KRAS GENE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MET GENE; MIDDLE AGED; NON SQUAMOUS CELL CARCINOMA; ONCOGENE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RET GENE; RETROSPECTIVE STUDY; ROS1 GENE; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA; STK11 GENE; TP53 GENE; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MASS SPECTROMETRY; MORTALITY; MULTICENTER STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; NUCLEOTIDE SEQUENCE; PHASE 3 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; DRUG COMBINATIONS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; OXONIC ACID; PACLITAXEL; TEGAFUR;

EID: 84899533736     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1906     Document Type: Article

References (30)

1. Siegel, R., Ma, J., Zou, Z., and Jemal, A. (2014) Cancer Statistics, 2014. CA Cancer J Clin
2. Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J. J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A., and Fukuoka, M. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361, 947-957
3. Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K., and Fukuoka, M. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11, 121-128
4. Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Ogura, T., Ando, M., Miyazawa, H., Tanaka, T., Saijo, Y., Hagiwara, K., Morita, S., and Nukiwa, T. (2010) Gefitinib or chemotherapy for nonsmall- cell lung cancer with mutated EGFR. N Engl J Med 362, 2380-2388
5. Zhou, C., Wu, Y. L., Chen, G., Feng, J., Liu, X. Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., and You, C. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol 12, 735-742
6. Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., Porta, R., Cobo, M., Garrido, P., Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M. A., Terrasa, J., Munoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J. L., Sanchez, J. J., Molina, M. A., Taron, M., and Paz-Ares, L. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13, 239-246
7. Sequist, L. V., Yang, J. C., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C. M., Boyer, M., Su, W. C., Bennouna, J., Kato, T., Gorbunova, V., Lee, K. H., Shah, R., Massey, D., Zazulina, V., Shahidi, M., and Schuler, M. (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31, 3327-3334
8. Pao, W., and Girard, N. (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12, 175-180
9. Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y., and Mano, H. (2007) Identification of the transforming EML4- ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566
10. Kwak, E. L., Bang, Y. J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. H., Dezube, B. J., Janne, P. A., Costa, D. B., Varella-Garcia, M., Kim, W. H., Lynch, T. J., Fidias, P., Stubbs, H., Engelman, J. A., Sequist, L. V., Tan, W., Gandhi, L., Mino-Kenudson, M., Wei, G. C., Shreeve, S. M., Ratain, M. J., Settleman, J., Christensen, J. G., Haber, D. A., Wilner, K., Salgia, R., Shapiro, G. I., Clark, J. W., and Iafrate, A. J. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363, 1693-1703
11. Shaw, A. T., Kim, D. W., Nakagawa, K., Seto, T., Crino, L., Ahn, M. J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., Wu, Y. L., Thomas, M., O'Byrne, K. J., Moro-Sibilot, D., Camidge, D. R., Mok, T., Hirsh, V., Riely, G. J., Iyer, S., Tassell, V., Polli, A., Wilner, K. D., and Janne, P. A. (2013) Crizotinib versus chemotherapy in advanced ALKpositive lung cancer. N Engl J Med 368, 2385-2394
12. Bergethon, K., Shaw, A. T., Ou, S. H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., Mark, E. J., Batten, J. M., Chen, H., Wilner, K. D., Kwak, E. L., Clark, J. W., Carbone, D. P., Ji, H., Engelman, J. A., Mino-Kenudson, M., Pao, W., and Iafrate, A. J. (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30, 863-870
13. Kohno, T., Ichikawa, H., Totoki, Y., Yasuda, K., Hiramoto, M., Nammo, T., Sakamoto, H., Tsuta, K., Furuta, K., Shimada, Y., Iwakawa, R., Ogiwara, H., Oike, T., Enari, M., Schetter, A. J., Okayama, H., Haugen, A., Skaug, V., Chiku, S., Yamanaka, I., Arai, Y., Watanabe, S., Sekine, I., Ogawa, S., Harris, C. C., Tsuda, H., Yoshida, T., Yokota, J., and Shibata, T. (2012) KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18, 375-377
14. Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., Lim Choi, Y., Satoh, Y., Okumura, S., Nakagawa, K., Mano, H., and Ishikawa, Y. (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18, 378- 381
15. Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jarosz, M., Curran, J. A., Balasubramanian, S., Bloom, T., Brennan, K. W., Donahue, A., Downing, S. R., Frampton, G. M., Garcia, L., Juhn, F., Mitchell, K. C., White, E., White, J., Zwirko, Z., Peretz, T., Nechushtan, H., Soussan-Gutman, L., Kim, J., Sasaki, H., Kim, H. R., Park, S. I., Ercan, D., Sheehan, C. E., Ross, J. S., Cronin, M. T., Janne, P. A., and Stephens, P. J. (2012) Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18, 382-384
16. Drilon, A., Wang, L., Hasanovic, A., Suehara, Y., Lipson, D., Stephens, P., Ross, J., Miller, V., Ginsberg, M., Zakowski, M. F., Kris, M. G., Ladanyi, M., and Rizvi, N. (2013) Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3, 630-635
17. Takeda, M., Okamoto, I., Fujita, Y., Arao, T., Ito, H., Fukuoka, M., Nishio, K., and Nakagawa, K. (2010) De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. J Thorac Oncol 5, 399-400
18. Li, T., Kung, H. J., Mack, P. C., and Gandara, D. R. (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31, 1039-1049
19. Okamoto, I., Yoshioka, H., Morita, S., Ando, M., Takeda, K., Seto, T., Yamamoto, N., Saka, H., Asami, K., Hirashima, T., Kudoh, S., Satouchi, M., Ikeda, N., Iwamoto, Y., Sawa, T., Miyazaki, M., Tamura, K., Kurata, T., Fukuoka, M., and Nakagawa, K. (2010) Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 28, 5240-5246
20. Yoshioka, H., Okamoto, I., Morita, S., Ando, M., Takeda, K., Seto, T., Yamamoto, N., Saka, H., Atagi, S., Hirashima, T., Kudoh, S., Satouchi, M., Ikeda, N., Iwamoto, Y., Sawa, T., Nakanishi, Y., and Nakagawa, K. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. Ann Oncol 24, 1326-1331
21. Tanizaki, J., Okamoto, I., Okamoto, K., Takezawa, K., Kuwata, K., Yamaguchi, H., and Nakagawa, K. (2011) MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol 6, 1624-1631
22. Ou, S. H., Kwak, E. L., Siwak-Tapp, C., Dy, J., Bergethon, K., Clark, J. W., Camidge, D. R., Solomon, B. J., Maki, R. G., Bang, Y. J., Kim, D. W., Christensen, J., Tan, W., Wilner, K. D., Salgia, R., and Iafrate, A. J. (2011) Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 6, 942-946
23. Schwab, R., Petak, I., Kollar, M., Pinter, F., Varkondi, E., Kohanka, A., Barti-Juhasz, H., Schonleber, J., Brauswetter, D., Kopper, L., and Urban, L. (2014) Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer 83, 109-111
24. Sakai, K., Okamoto, I., Takezawa, K., Hirashima, T., Kaneda, H., Takeda, M., Matsumoto, K., Kimura, H., Fujita, Y., Nakagawa, K., Arao, T., and Nishio, K. (2012) A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer. J Thorac Oncol 7, 913-918
25. Sequist, L. V., Heist, R. S., Shaw, A. T., Fidias, P., Rosovsky, R., Temel, J. S., Lennes, I. T., Digumarthy, S., Waltman, B. A., Bast, E., Tammireddy, S., Morrissey, L., Muzikansky, A., Goldberg, S. B., Gainor, J., Channick, C. L., Wain, J. C., Gaissert, H., Donahue, D. M., Muniappan, A., Wright, C., Willers, H., Mathisen, D. J., Choi, N. C., Baselga, J., Lynch, T. J., Ellisen, L. W., Mino-Kenudson, M., Lanuti, M., Borger, D. R., Iafrate, A. J., Engelman, J. A., and Dias-Santagata, D. (2011) Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 22, 2616-2624
26. Suda, K., Tomizawa, K., and Mitsudomi, T. (2010) Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 29, 49-60
27. Rimkunas, V. M., Crosby, K. E., Li, D., Hu, Y., Kelly, M. E., Gu, T. L., Mack, J. S., Silver, M. R., Zhou, X., and Haack, H. (2012) Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 18, 4449-4457
28. Kim, H. R., Lim, S. M., Kim, H. J., Hwang, S. K., Park, J. K., Shin, E., Bae, M. K., Ou, S. H., Wang, J., Jewell, S. S., Kang, D. R., Soo, R. A., Haack, H., Kim, J. H., Shim, H. S., and Cho, B. C. (2013) The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol 24, 2364-2370
29. Sadiq, A. A., and Salgia, R. (2013) MET as a possible target for non-small-cell lung cancer. J Clin Oncol 31, 1089-1096
30. Wolff, A. C., Hammond, M. E., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M., Bilous, M., Fitzgibbons, P., Hanna, W., Jenkins, R. B., Mangu, P. B., Paik, S., Perez, E. A., Press, M. F., Spears, P. A., Vance, G. H., Viale, G., and Hayes, D. F. (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31, 3997- 4013